| $337M | ||
| $259M | ||
| $100M | ||
| $79M | ||
| $60M | ||
| $58M |
Buys | $63,800 | 1 | 17 |
Sells | $482,111 | 5 | 83 |
| Levy Richard S | director | 1 | $63,800 | 0 | $0 | $63,800 |
| Zummo Jacqueline | Chf Scientific Operations Off | 0 | $0 | 1 | $96,145 | $-96,145 |
| Opaleye Management Inc. | 10 percent owner | 0 | $0 | 4 | $385,966 | $-385,966 |
Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the identifying and advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy for the treatment of lymphatic malformations. It also develops intravenous choline chloride, an investigational phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease. The company was formerly known as ArTara Therapeutics, Inc. and changed its name to Protara Therapeutics, Inc. in May 2020. Protara Therapeutics, Inc. is headquartered in New York, New York.
Over the last 12 months, insiders at Protara Therapeutics, Inc. have bought $63,800 and sold $482,111 worth of Protara Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Protara Therapeutics, Inc. have bought $1.74M and sold $870,395 worth of stock each year.
Highest buying activity among insiders over the last 12 months: Levy Richard S (director) — $63,800.
The last purchase of 20,000 shares for transaction amount of $63,800 was made by Levy Richard S (director) on 2025‑05‑14.
| 2025-05-14 | Levy Richard S | director | 20,000 0.0528% | $3.19 | $63,800 | 0.00% | ||
| 2025-03-26 | Sale | Zummo Jacqueline | Chf Scientific Operations Off | 21,224 0.0577% | $4.53 | $96,145 | -27.92% | |
| 2024-09-12 | Sale | Opaleye Management Inc. | 10 percent owner | 126,301 0.6048% | $1.71 | $215,836 | +94.80% | |
| 2024-09-11 | Sale | Opaleye Management Inc. | 10 percent owner | 32,600 0.1566% | $1.71 | $55,880 | +98.24% | |
| 2024-09-10 | Sale | Opaleye Management Inc. | 10 percent owner | 25,500 0.1264% | $1.77 | $45,110 | +94.80% | |
| 2024-09-09 | Sale | Opaleye Management Inc. | 10 percent owner | 36,492 0.1821% | $1.89 | $69,141 | +82.88% | |
| 2024-07-16 | Sale | Opaleye Management Inc. | 10 percent owner | 11,396 0.0691% | $2.44 | $27,828 | +31.46% | |
| 2024-07-11 | Sale | Opaleye Management Inc. | 10 percent owner | 47,993 0.2866% | $2.40 | $115,346 | +34.83% | |
| 2024-07-10 | Sale | Opaleye Management Inc. | 10 percent owner | 18,061 0.1036% | $2.31 | $41,685 | +36.58% | |
| 2024-07-09 | Sale | Opaleye Management Inc. | 10 percent owner | 8,497 0.0467% | $2.21 | $18,811 | +48.12% | |
| 2024-07-01 | Sale | Opaleye Management Inc. | 10 percent owner | 8,288 0.0437% | $2.12 | $17,598 | +50.48% | |
| 2024-06-28 | Sale | Opaleye Management Inc. | 10 percent owner | 17,994 0.0927% | $2.07 | $37,334 | +51.44% | |
| 2024-06-27 | Sale | Opaleye Management Inc. | 10 percent owner | 46,574 0.2613% | $2.26 | $105,169 | +44.93% | |
| 2024-06-25 | Sale | Opaleye Management Inc. | 10 percent owner | 12,725 0.0665% | $2.26 | $28,734 | +49.76% | |
| 2024-05-31 | Sale | Opaleye Management Inc. | 10 percent owner | 5,824 0.0292% | $2.90 | $16,895 | +2.85% | |
| 2024-05-30 | Sale | Opaleye Management Inc. | 10 percent owner | 9,230 0.0454% | $2.94 | $27,113 | -1.55% | |
| 2024-05-22 | Sale | Opaleye Management Inc. | 10 percent owner | 9,800 0.0481% | $3.02 | $29,596 | -6.35% | |
| 2024-05-21 | Sale | Opaleye Management Inc. | 10 percent owner | 33,000 0.1671% | $3.06 | $100,838 | -4.44% | |
| 2024-05-17 | Sale | Opaleye Management Inc. | 10 percent owner | 70,885 0.3032% | $3.25 | $230,326 | -9.39% | |
| 2024-05-10 | Sale | Opaleye Management Inc. | 10 percent owner | 151,700 0.7648% | $3.11 | $472,424 | -6.67% |
| Zummo Jacqueline | Chf Scientific Operations Off | 98861 0.2562% | $304,491.88 | 0 | 1 | |
| Levy Richard S | director | 51000 0.1322% | $157,080.00 | 1 | 0 | |
| Opaleye Management Inc. | 10 percent owner | 45000 0.1166% | $138,600.00 | 15 | 20 | <0.0001% |
| O'Leary Brendan | director | 1387198 3.5955% | $4.27M | 1 | 0 | |
| Abingworth LLP | 10 percent owner | 950000 2.4623% | $2.93M | 1 | 0 | |
| Haines Timothy | 950000 2.4623% | $2.93M | 1 | 0 | ||
| Shefferman Jesse | CEO and President | 879441 2.2794% | $2.71M | 1 | 0 | <0.0001% |
| Pharmstandard International S.A. | 10 percent owner | 600000 1.5551% | $1.85M | 1 | 0 | |
| Kobyzev Dmitry | 600000 1.5551% | $1.85M | 1 | 0 | ||
| Marshall Randall | 585600 1.5178% | $1.8M | 0 | 27 | ||
| Birner Hubert | 300000 0.7776% | $924,000.00 | 1 | 0 | ||
| TVM Life Science Ventures VI GmbH & Co KG | 10 percent owner | 300000 0.7776% | $924,000.00 | 1 | 0 | |
| Freund John Gordon | 200000 0.5184% | $616,000.00 | 1 | 1 | ||
| Skyline Venture Partners Qualified Purchaser Fund IV L P | 10 percent owner | 200000 0.5184% | $616,000.00 | 1 | 1 | |
| BESHAR LUKE M | 198000 0.5132% | $609,840.00 | 3 | 0 | <0.0001% | |
| Flynn James E | director | 197424 0.5117% | $608,065.92 | 2 | 1 | |
| Burke Steven Keith | SVP and Chief Medical Officer | 117535 0.3046% | $362,007.80 | 1 | 0 | |
| Olivo Martin Sebastian | Chief Medical Officer | 14344 0.0372% | $44,179.52 | 1 | 0 | <0.0001% |
| Eldridge, George Arthur | Sr VP, CFO, Treasr, Asst Secy | 1545 0.004% | $4,758.60 | 2 | 0 | |
| Davis Blaine | Chief Financial Officer | 1481 0.0038% | $4,561.48 | 1 | 0 | <0.0001% |
| NOYES TIMOTHY P | President and CEO | 0 0% | $0 | 0 | 5 | |
| Gottlieb Daniel Philip | VP Marketing & Bus Development | 0 0% | $0 | 0 | 1 |
$5,102,291 | 146 | 5.58% | $110.81M | |
$30,470,407 | 140 | 20.39% | $106.76M | |
$48,218,096 | 42 | 0.89% | $125.2M | |
$909,129 | 37 | 42.19% | $110.75M | |
Protara Therapeutics, Inc. (TARA) | $6,915,275 | 21 | -32.61% | $118.83M |
$294,424,120 | 20 | 1.33% | $129.54M | |
$33,027,560 | 17 | -10.02% | $105.49M | |
$4,701,608 | 14 | -4.34% | $115.43M | |
$73,968,137 | 12 | -34.52% | $135.06M | |
$145,194 | 11 | -27.37% | $108.75M | |
$1,073,250 | 10 | 19.46% | $125.66M | |
$9,999,920 | 10 | -40.03% | $128.37M | |
$478,647 | 7 | 69.41% | $124.34M | |
$22,090,972 | 7 | -3.49% | $132.51M | |
$68,692,148 | 6 | -39.10% | $124.17M | |
$4,745,999 | 5 | -4.91% | $118.18M | |
$762,555 | 4 | -34.52% | $111.9M | |
$59,900 | 4 | -5.37% | $118.39M | |
$19,175,155 | 2 | 40.00% | $122.87M |
| Increased Positions | 32 | +55.17% | 5M | +16.54% |
| Decreased Positions | 21 | -36.21% | 6M | -19.53% |
| New Positions | 8 | New | 471,986 | New |
| Sold Out Positions | 9 | Sold Out | 5M | Sold Out |
| Total Postitions | 69 | +18.97% | 30M | -2.99% |
| Ra Capital Management, L.P. | $12,172.00 | 8.72% | 3.4M | +2M | +78.95% | 2024-12-31 |
| Janus Henderson Group Plc | $8,133.00 | 5.83% | 2.27M | +2M | New | 2024-12-31 |
| Adage Capital Partners Gp, L.L.C. | $8,055.00 | 5.77% | 2.25M | +2M | New | 2024-12-31 |
| Toronto Dominion Bank | $7,478.00 | 5.36% | 2.09M | +2M | New | 2024-12-31 |
| Opaleye Management Inc. | $6,534.00 | 4.68% | 1.82M | +143,846 | +8.56% | 2024-12-31 |
| Blackstone Inc. | $6,014.00 | 4.31% | 1.68M | +2M | New | 2024-12-31 |
| Velan Capital Investment Management Lp | $5,653.00 | 4.05% | 1.58M | +1M | +175.09% | 2024-12-31 |
| Sio Capital Management, Llc | $5,146.00 | 3.69% | 1.44M | +1M | New | 2024-12-31 |
| Integral Health Asset Management, Llc | $5,012.00 | 3.59% | 1.4M | +1M | New | 2024-12-31 |
| Vanguard Group Inc | $4,867.00 | 3.49% | 1.36M | +599,897 | +78.97% | 2024-12-31 |